Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.24 USD
Change Today +0.06 / 0.84%
Volume 467.1K
As of 12:45 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Mark L. Bagarazzi M.D.

Chief Medical Officer, Inovio Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

As of Fiscal Year 2014


Mark L. Bagarazzi, M.D. has been the Chief Medical Officer of Inovio Pharmaceuticals, Inc. since January 2010. Dr. Bagarazzi leads worldwide clinical development and regulatory activities for Inovio's next-generation vaccines for the treatment and prevention of influenza, HIV, other infectious diseases and cancers. He joined Inovio from Merck & Co., where he was Director of worldwide regulatory affairs for vaccines and biologics. Dr. Bagarazzi led ongoing vaccine product ...

Read Full Background

Corporate Headquarters*

660 West Germantown Pike
Plymouth Meeting, Pennsylvania 19462

United States

Phone: 267-440-4200
Fax: 267-440-4242

Board Members Memberships*

There is no Board Members Memberships data available.


University of Medicine and Dentistry of New Jersey
New Jersey Institute Of Technology

Other Affiliations*

Annual Compensation*

Total Annual Compensation$491,069

Stock Options*

All Other Compensation$10,817
Exercisable Options173,123
Unexercisable Options90,627
Total Number of Options263,750

Total Compensation*

Total Annual Cash Compensation$501,886
Total Short Term Compensation$491,069
Other Long Term Compensation$10,817
Total Calculated Compensation$1,161,761
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $7.24 USD +0.06


Vijay B. Samant Chief Executive Officer, President, Acting Chief Financial Officer and Director
Vical Incorporated
Philippe Archinard Ph.D.Chairman and Chief Executive Officer
Transgene SA
Eddie Gray Chief Executive Officer and Director
Dynavax Technologies Corporation
Daniel J. O'Connor Esq.Chief Executive Officer, President and Director
Advaxis, Inc.
William D. Clark Chief Executive Officer, President and Director
Genocea Biosciences, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOVIO PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at